Holen Sie sich die Stockscreener-App
3.98
3.38%
0.13
Handel nachbörslich:
4.06
0.08
+2.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.85
Offen:
$3.82
24-Stunden-Volumen:
18.14M
Relative Volume:
1.17
Marktkapitalisierung:
$1.78B
Einnahmen:
$263.44M
Nettoeinkommen (Verlust:
$-390.98M
KGV:
-3.5504
EPS:
-1.121
Netto-Cashflow:
$-336.24M
1W Leistung:
+17.75%
1M Leistung:
+16.03%
6M Leistung:
+119.89%
1J Leistung:
+13.71%
1-Tages-Spanne:
$3.80
$4.00
1-Wochen-Bereich:
$3.27
$4.00
52-Wochen-Spanne:
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.98 | 1.72B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Stock Short Interest Falls to 32.69% - Quiver Quantitative
IOVA Stock Rises As Rival’s FDA Setback Lifts Amtagvi - StocksToTrade
IOVA Stock Draws Bullish Calls As Rival Stumbles On FDA Setback - timothysykes.com
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com
CM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics | ARS: Annual Report to Security Holders - Moomoo
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - AOL.com
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - The Motley Fool
IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN
Iovance’s Plan to Lift Authorized Shares to 650 Million Could Be A Game Changer For Iovance Biotherapeutics (IOVA) - Sahm
[ARS] IOVANCE BIOTHERAPEUTICS, INC. SEC Filing - Stock Titan
MSN Money - MSN
IOVA Earnings History & Surprises | EPS & Revenue Results | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics senior executive joins cancer research panel to promote flexible innovation in immunotherapy - Traders Union
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Iovance Biotherapeutics (IOVA) to Post Earnings on Thursday - MarketBeat
Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding - Yahoo Finance
Iovance Biotherapeutics | DEFA14A: Others - Moomoo
Iovance Biotherapeutics | DEF 14A: Definitive information statements - Moomoo
Iovance (NASDAQ: IOVA) seeks approval to raise authorized common shares to 650M - Stock Titan
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out (NASDAQ:IOVA) - Seeking Alpha
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery And Undervalued Narrative - Sahm
IOVA shares jump 8% — what’s retail expecting? - MSN
May 7 at 8:30 ET: Iovance to give Q1 results and updates - Stock Titan
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 - Yahoo Finance
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Iovance Biotherapeutics (IOVA) down 2.1% since last earnings report: Can it rebound? - MSN
Chardan Capital Maintains Iovance Biotherapeutics (IOVA) Buy Recommendation - MSN
Iovance falls after guidance cut, revenue miss - MSN
Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative? - Sahm
IOVA Forecast, Price Target & Analyst Ratings | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4%Here's What Happened - MarketBeat
IOVA Stock Grinds Lower As Traders Watch Key Support - StocksToTrade
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug - Insider Monkey
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Iovance Biotherapeutics (IOVA) - The Globe and Mail
Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA) - Insider Monkey
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics (NASDAQ: IOVA) seeks votes on ESPP + share increase - Stock Titan
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? - Yahoo Finance
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Three Month Share Price Surge - Sahm
Chardan Capital Lowers Price Target for IOVA, Maintains Buy Rati - GuruFocus
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):